Monte Rosa Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $8,968 | $4,210 | $2,781 | $12,768 |
Gross Profit | 8,968 | 2,181 | 2,781 | 12,768 |
EBITDA | -41,275 | -42,422 | -43,988 | -28,163 |
EBIT | -43,189 | -44,451 | -46,076 | -30,258 |
Net Income | -43,397 | -44,503 | -46,135 | -27,081 |
Net Change In Cash | 8,968 | 4,210 | 2,781 | 12,768 |
Free Cash Flow | -88,074 | -39,237 | -43,781 | 99,777 |
Cash | 90,104 | 159,859 | 129,883 | 208,343 |
Basic Shares | 85,226 | 84,321 | 65,543 | 61,790 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $123,672 | $75,622 | $0 | $0 |
Gross Profit | 115,316 | 67,501 | -6,222 | -8,559 |
EBITDA | -31,367 | -62,009 | -128,792 | -100,992 |
EBIT | -39,723 | -70,130 | -135,014 | -104,737 |
Net Income | -38,626 | -72,700 | -135,352 | -108,501 |
Net Change In Cash | 123,672 | 75,622 | 0 | 0 |
Cost of Revenue | -291,219 | |||
Free Cash Flow | -27,498 | 38,008 | -62,843 | -105,377 |
Cash | 129,883 | 224,254 | 128,101 | 54,912 |
Basic Shares | 65,543 | 73,910 | 51,396 | 47,227 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.43 |
2026-03-31 | -$0.45 |
2025-12-31 | -$0.55 |
2025-09-30 | -$0.33 |